Compare BridgeBio Pharma Inc (BBIO) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Innovative Industrial Properties Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Innovative Industrial Properties Inc trades at $58.5 (market cap $1.67B). The key difference: BridgeBio Pharma Inc is far larger — about 9.8× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | IIPR | |
|---|---|---|
Market Cap | $16.36B | $1.67B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $64.67 |
52-Week Low | $47.29 | $44.58 |
Enterprise Value | $18.14B | $2.21B |
Dividend Yield | — | 13.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
Innovative Industrial Properties (IIPR) trades at $57.84, up 0.63% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 revenue of $63.3 million and FFO of $1.83 per share, beating estimates. Financials show strong gross margins of 88.35% but declining revenue from $266 million in 2025 to $264 million in 2026. Recent news highlights institutional buying and dividend sustainability debates amid tenant distress concerns.
Outlook remains mixed with a discounted P/E of 13.05 and high dividend yield offering value, but risks include revenue contraction, tenant diversification issues, and bearish technical trends. Analyst consensus is cautious with 36% buy ratings. The stock presents income appeal but requires monitoring of operational execution and cannabis sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
